News Sentiment

MIRA sentiment intelligence

MIRA Pharmaceuticals, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 30 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 0.92 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

77/100 classification confidence.

Company focus 30

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-2.1% over one week, -1.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 77/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend inactive -1.6% over four weeks
Fair value -41.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 21
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 30
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 7
Stock Titan 5
www.marketscreener.com 3
Moomoo 2
AskTraders 2
DonanımHaber 1
Ad-hoc-news.de 1
24/7 Wall St. 1

Event Lens

What the news is about

Classified themes
Earnings 14
Market update 14
Analyst action 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 30
Stock Titan Direct company coverage

MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55

MIRA Pharmaceuticals announced positive preclinical results for MIRA-55, its non-opioid drug candidate for chronic inflammatory pain. The company selected an optimized oral formulation that showed favorable oral bioavailability, sustained systemic exposure, and reproducible distr

Tone
Positive 72/100
Event
Earnings
Published
10 Jul 2026 12:09
Source
Stock Titan
Moomoo Direct company coverage

Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies

Mira Pharmaceuticals (NASDAQ:MIRA) announced that its obesity and addiction drug candidate, SKNY-1, demonstrated favorable bioavailability and brain penetration in preclinical pharmacokinetic studies. These results support the drug's potential for once-daily oral dosing and its a

Tone
Positive 74/100
Event
Earnings
Published
07 Jul 2026 02:10
Source
Moomoo
Stock Titan Direct company coverage

MIRA's obesity-and-addiction drug shows brain and liver exposure

MIRA Pharmaceuticals (NASDAQ:MIRA) reported positive preclinical results for SKNY-1, an oral drug candidate for obesity and addiction. The optimized formulation demonstrated favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial

Tone
Positive 93/100
Event
Earnings
Published
06 Jul 2026 13:10
Source
Stock Titan
www.marketscreener.com Direct company coverage

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark

MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA) has been added to the Russell 3000E Growth Benchmark. This addition highlights the company's growth trajectory and its increasing recognition within the financial markets. MIRA Pharmaceuticals is a clinical-stage company focused on deve

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:38
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index

MIRA Pharmaceuticals, Inc. (NasdaqCM:MIRA) has been added to the Russell Microcap Growth Benchmark Index. The company is a clinical-stage pharmaceutical firm focused on developing therapeutics for neurological, neuropsychiatric, and metabolic disorders. Its pipeline includes oral

Tone
Positive 93/100
Event
Market update
Published
29 Jun 2026 12:12
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index

MIRA Pharmaceuticals (NasdaqCM: MIRA), a clinical-stage pharmaceutical company, has been added to the Russell 3000E Index. The company focuses on developing therapeutics for neurologic, neuropsychiatric, and metabolic disorders, with a pipeline that includes drug candidates for n

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 03:09
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA

This article provides financial information for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a section from a larger financial data platform, indicating the company's status on the Nasdaq Stock Ma

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 04:38
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA

This article provides financial information for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) focusing on its price-to-earnings forward metric. It details the company's presence on the Nasdaq Stock Market and references data from ICE Data Services, FactSet, and Quartr for financial r

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 04:08
Source
TradingView
TradingView Direct company coverage

MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S)

This article provides an overview of MIRA Pharmaceuticals, Inc. (FWB:K6S), including financial actuals and estimates, stock forecasts, and company information. According to analysts, the stock has a maximum estimate of 8.18 EUR and a minimum estimate of 8.18 EUR, with the next ea

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:40
Source
TradingView
TradingView Direct company coverage

MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S)

This article provides an overview of MIRA Pharmaceuticals, Inc. (K6S) stock performance and financial data on the Munich Stock Exchange. It includes analyst forecasts, historical price data, upcoming earnings report dates, and key financial figures such as net income and employee

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA

This article focuses on the enterprise value to revenue forward metric for MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). It appears to be a stub or data placeholder from TradingView, indicating that specific financial data for this metric is expected to be displayed. The content pro

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 22:40
Source
TradingView
TradingView Direct company coverage

MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S)

This article provides an overview of MIRA Pharmaceuticals, Inc. (TRADEGATE:K6S) including financial actuals and estimates. It details analyst forecasts for the stock, its historical highs and lows, upcoming earnings reports, recent net income, dividend policy (none), and employee

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 02:11
Source
TradingView